Autologous T cells engineered to express a chimeric antigen receptor (CAR) remain poorly effective against solid tumors, partly because solid neoplasms can establish an immunosuppressive microenvironment. Recent findings by Srivastava et al. suggest that immunogenic chemotherapeutics such as oxaliplatin can be harnessed to maximize the capacity of CAR T cells to infiltrate and control solid tumors.
Immunogenic Therapies Drive CAR T Cells towards Superior Efficacy / Petroni, Giulia; Kroemer, Guido; Galluzzi, Lorenzo. - In: TRENDS IN CANCER. - ISSN 2405-8025. - ELETTRONICO. - 7:(2021), pp. 179-181. [10.1016/j.trecan.2021.01.005]
Immunogenic Therapies Drive CAR T Cells towards Superior Efficacy
Petroni, Giulia;Galluzzi, Lorenzo
2021
Abstract
Autologous T cells engineered to express a chimeric antigen receptor (CAR) remain poorly effective against solid tumors, partly because solid neoplasms can establish an immunosuppressive microenvironment. Recent findings by Srivastava et al. suggest that immunogenic chemotherapeutics such as oxaliplatin can be harnessed to maximize the capacity of CAR T cells to infiltrate and control solid tumors.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
